Lead Sponsor

AbbVie (prior sponsor, Abbott)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Pathologically documented NSCLC
•Locally advanced (Stage III) or metastatic (Stage IV) NSCLC
•Only one prior anti-tumor treatment regimen in the non-curative setting (i.e., 2nd-line therapy)
•Only one prior anti-tumor treatment regimen in the curative setting
•Progressive disease following the previous anti-tumor treatment regimen
•Measurable disease by RECIST criteria
•Brain metastasis must be stable and well-controlled
•ECOG performance score 0-2
•All anti-tumor therapy discontinued at least 3 weeks prior to study entry
•All adverse events from prior treatment are resolved or stable
•Adequate hematologic, renal, and hepatic function
•Females must not be pregnant
•Willing to take adequate measures to prevent pregnancy
•Life expectancy of at least 3 months
•Able to complete the Quality of Life questionnaire
•Voluntarily signed informed consent

•Greater than Grade 1 neurological findings
•Allergy to sulfa medications
•Previous treatment with ABT-751 or pemetrexed
•Receipt of more than one investigational agent for NSCLC
•Significant weight loss (\>10%) within 6 weeks of study entry
•Glucose-6-phosphate dehydrogenase deficiency or porphyria
•Significant systemic disease that would adversely affect participation
•Class 3-4 New York Heart Association classification status
•Other cancers except in situ carcinoma of the cervix, basal or squamous cell skin cancer, or any other cancer considered adequately treated and cured by the investigator

Related studies

NCT06312137 · Non Small Cell Lung Cancer

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

NCT07444437 · Non-Small Cell Lung Cancer

NCT07489716 · Non-Small Cell Lung Cancer

NCT07308106 · Non-small Lung Cancer

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer